[
  {
    "id": "drug-metoprolol",
    "name": { "en": "Metoprolol", "cs": "Metoprolol" },
    "class": { "en": "Beta-1 selective blocker", "cs": "Selektivní beta-1 blokátor" },
    "indications": { "en": "Hypertension, angina, rate control", "cs": "Hypertenze, angina, kontrola frekvence" },
    "mechanism": { "en": "Blocks beta-1 receptors reducing heart rate and contractility", "cs": "Blokuje beta-1 receptory, snižuje tep a kontraktilitu" },
    "adverseEffects": { "en": "Bradycardia, fatigue, dizziness", "cs": "Bradykardie, únava, závratě" },
    "contraindications": { "en": "Severe bradycardia, high-degree AV block", "cs": "Těžká bradykardie, vysokostupňový AV blok" },
    "monitoring": { "en": "Heart rate, blood pressure", "cs": "Srdeční frekvence, krevní tlak" },
    "interactionsSummary": { "en": "Additive bradycardia with non-DHP CCBs", "cs": "Přídavná bradykardie s verapamilem/diltiazemem" },
    "typicalDoseText": { "en": "25–100 mg PO BID (educational)", "cs": "25–100 mg p.o. 2× denně (výukově)" },
    "tags": ["beta-blocker", "antihypertensive"],
    "courseBlockId": "block-cv"
  },
  {
    "id": "drug-amlodipine",
    "name": { "en": "Amlodipine", "cs": "Amlodipin" },
    "class": { "en": "Dihydropyridine calcium channel blocker", "cs": "Dihydropyridinový blokátor kalciových kanálů" },
    "indications": { "en": "Hypertension, angina", "cs": "Hypertenze, angina" },
    "mechanism": { "en": "Vasodilates peripheral arteries via L-type calcium channel blockade", "cs": "Vasodilatuje periferní tepny blokádou L-typ kalciových kanálů" },
    "adverseEffects": { "en": "Edema, headache, flushing", "cs": "Edém, bolest hlavy, návaly" },
    "contraindications": { "en": "Severe hypotension", "cs": "Těžká hypotenze" },
    "monitoring": { "en": "Blood pressure, edema", "cs": "Krevní tlak, edémy" },
    "interactionsSummary": { "en": "Additive hypotension with other vasodilators", "cs": "Přídavná hypotenze s jinými vazodilatátory" },
    "typicalDoseText": { "en": "5–10 mg PO daily (educational)", "cs": "5–10 mg p.o. denně (výukově)" },
    "tags": ["ccb", "antihypertensive"],
    "courseBlockId": "block-cv"
  },
  {
    "id": "drug-lisinopril",
    "name": { "en": "Lisinopril", "cs": "Lisinopril" },
    "class": { "en": "ACE inhibitor", "cs": "ACE inhibitor" },
    "indications": { "en": "Hypertension, heart failure", "cs": "Hypertenze, srdeční selhání" },
    "mechanism": { "en": "Inhibits ACE reducing angiotensin II and aldosterone", "cs": "Inhibuje ACE, snižuje angiotensin II a aldosteron" },
    "adverseEffects": { "en": "Cough, hyperkalemia, angioedema (rare)", "cs": "Kašel, hyperkalemie, angioedém (vzácně)" },
    "contraindications": { "en": "Pregnancy, history of angioedema", "cs": "Těhotenství, anamnéza angioedému" },
    "monitoring": { "en": "Blood pressure, potassium, creatinine", "cs": "Krevní tlak, draslík, kreatinin" },
    "interactionsSummary": { "en": "Risk of hyperkalemia with potassium-sparing agents", "cs": "Riziko hyperkalemie s kalium šetřícími látkami" },
    "typicalDoseText": { "en": "10–40 mg PO daily (educational)", "cs": "10–40 mg p.o. denně (výukově)" },
    "tags": ["acei", "heart-failure"],
    "courseBlockId": "block-cv"
  },
  {
    "id": "drug-warfarin",
    "name": { "en": "Warfarin", "cs": "Warfarin" },
    "class": { "en": "Vitamin K antagonist", "cs": "Antagonista vitaminu K" },
    "indications": { "en": "Atrial fibrillation, VTE prevention", "cs": "Fibrilace síní, prevence TEN" },
    "mechanism": { "en": "Inhibits vitamin K–dependent clotting factor synthesis", "cs": "Inhibuje syntézu koagulačních faktorů závislých na vitaminu K" },
    "adverseEffects": { "en": "Bleeding, skin necrosis (rare)", "cs": "Krvácení, kožní nekróza (vzácně)" },
    "contraindications": { "en": "Pregnancy, active bleeding", "cs": "Těhotenství, aktivní krvácení" },
    "monitoring": { "en": "INR, signs of bleeding", "cs": "INR, známky krvácení" },
    "interactionsSummary": { "en": "Many CYP and dietary interactions", "cs": "Mnoho CYP a dietních interakcí" },
    "typicalDoseText": { "en": "Titrate to INR 2–3 (educational)", "cs": "Titrace na INR 2–3 (výukově)" },
    "tags": ["anticoagulant"],
    "courseBlockId": "block-cv"
  },
  {
    "id": "drug-amoxicillin",
    "name": { "en": "Amoxicillin", "cs": "Amoxicilin" },
    "class": { "en": "Aminopenicillin", "cs": "Aminopenicilin" },
    "indications": { "en": "ENT, respiratory infections", "cs": "ORL, respirační infekce" },
    "mechanism": { "en": "Inhibits bacterial cell wall synthesis", "cs": "Inhibuje syntézu bakteriální stěny" },
    "adverseEffects": { "en": "Rash, diarrhea", "cs": "Exantém, průjem" },
    "contraindications": { "en": "Severe penicillin allergy", "cs": "Těžká alergie na penicilin" },
    "monitoring": { "en": "Clinical response", "cs": "Klinická odpověď" },
    "interactionsSummary": { "en": "Reduced effect with some bacteriostatics", "cs": "Snížený účinek s některými bakteriostatiky" },
    "typicalDoseText": { "en": "500–875 mg PO q8–12h (educational)", "cs": "500–875 mg p.o. každých 8–12 h (výukově)" },
    "tags": ["penicillin", "antibiotic"],
    "courseBlockId": "block-abx"
  },
  {
    "id": "drug-azithromycin",
    "name": { "en": "Azithromycin", "cs": "Azithromycin" },
    "class": { "en": "Macrolide", "cs": "Makrolid" },
    "indications": { "en": "Respiratory, atypical infections", "cs": "Respirační, atypické infekce" },
    "mechanism": { "en": "Binds 50S ribosome inhibiting protein synthesis", "cs": "Váže se na 50S ribozom, inhibuje syntézu proteinů" },
    "adverseEffects": { "en": "GI upset, QT prolongation", "cs": "GIT potíže, prodloužení QT" },
    "contraindications": { "en": "Significant QT prolongation", "cs": "Výrazné prodloužení QT" },
    "monitoring": { "en": "ECG if high risk", "cs": "EKG u rizikových pacientů" },
    "interactionsSummary": { "en": "QT prolonging agents additive", "cs": "Adice prodloužení QT s jinými látkami" },
    "typicalDoseText": { "en": "500 mg day 1 then 250 mg daily (educational)", "cs": "500 mg 1. den, poté 250 mg denně (výukově)" },
    "tags": ["macrolide", "qt"],
    "courseBlockId": "block-abx"
  },
  {
    "id": "drug-vancomycin",
    "name": { "en": "Vancomycin", "cs": "Vankomycin" },
    "class": { "en": "Glycopeptide", "cs": "Glykopeptid" },
    "indications": { "en": "Serious Gram+ infections, MRSA", "cs": "Závažné G+ infekce, MRSA" },
    "mechanism": { "en": "Inhibits cell wall synthesis by binding D-Ala-D-Ala", "cs": "Inhibuje syntézu stěny vazbou na D-Ala-D-Ala" },
    "adverseEffects": { "en": "Nephrotoxicity, Red man syndrome", "cs": "Nefrotoxicita, syndrom rudého muže" },
    "contraindications": { "en": "Hypersensitivity", "cs": "Hypersenzitivita" },
    "monitoring": { "en": "Renal function, levels per protocol", "cs": "Renální funkce, hladiny dle protokolu" },
    "interactionsSummary": { "en": "Nephrotoxicity with other nephrotoxins", "cs": "Nefrotoxicita s dalšími nefrotoxickými látkami" },
    "typicalDoseText": { "en": "15–20 mg/kg IV q8–12h (educational)", "cs": "15–20 mg/kg i.v. každých 8–12 h (výukově)" },
    "tags": ["glycopeptide", "mrsa"],
    "courseBlockId": "block-abx"
  },
  {
    "id": "drug-sertraline",
    "name": { "en": "Sertraline", "cs": "Sertralin" },
    "class": { "en": "SSRI", "cs": "SSRI" },
    "indications": { "en": "Depression, anxiety", "cs": "Deprese, úzkost" },
    "mechanism": { "en": "Selectively inhibits serotonin reuptake", "cs": "Selektivně inhibuje zpětné vychytávání serotoninu" },
    "adverseEffects": { "en": "GI upset, insomnia, sexual dysfunction", "cs": "GIT potíže, nespavost, sexuální dysfunkce" },
    "contraindications": { "en": "MAOI use", "cs": "Současné užívání MAOI" },
    "monitoring": { "en": "Mood, suicidality early", "cs": "Nálada, suicidální myšlenky v úvodu" },
    "interactionsSummary": { "en": "Serotonin syndrome with other serotonergics", "cs": "Serotoninový syndrom s dalšími serotoninergními látkami" },
    "typicalDoseText": { "en": "50–200 mg PO daily (educational)", "cs": "50–200 mg p.o. denně (výukově)" },
    "tags": ["ssri", "antidepressant"],
    "courseBlockId": "block-cns"
  },
  {
    "id": "drug-lorazepam",
    "name": { "en": "Lorazepam", "cs": "Lorazepam" },
    "class": { "en": "Benzodiazepine", "cs": "Benzodiazepin" },
    "indications": { "en": "Anxiety, status epilepticus", "cs": "Úzkost, status epilepticus" },
    "mechanism": { "en": "Enhances GABA-A activity increasing Cl- influx", "cs": "Zvyšuje aktivitu GABA-A, zvyšuje influx Cl-" },
    "adverseEffects": { "en": "Sedation, respiratory depression (IV)", "cs": "Sedace, respirační deprese (i.v.)" },
    "contraindications": { "en": "Severe respiratory insufficiency", "cs": "Těžká respirační insuficience" },
    "monitoring": { "en": "Sedation, respiration if IV", "cs": "Sedace, ventilace při i.v." },
    "interactionsSummary": { "en": "Additive CNS depression with alcohol/opioids", "cs": "Additivní CNS deprese s alkoholem/opioidy" },
    "typicalDoseText": { "en": "0.5–2 mg PO TID PRN (educational)", "cs": "0,5–2 mg p.o. 3× denně dle potřeby (výukově)" },
    "tags": ["benzodiazepine", "cns"],
    "courseBlockId": "block-cns"
  },
  {
    "id": "drug-insulin-glargine",
    "name": { "en": "Insulin glargine", "cs": "Inzulin glargin" },
    "class": { "en": "Long-acting insulin", "cs": "Dlouhodobě působící inzulin" },
    "indications": { "en": "Basal insulin for diabetes", "cs": "Bazální inzulin pro diabetes" },
    "mechanism": { "en": "Binds insulin receptor to increase glucose uptake", "cs": "Váže inzulinový receptor, zvyšuje příjem glukózy" },
    "adverseEffects": { "en": "Hypoglycemia, weight gain", "cs": "Hypoglykémie, přibývání na váze" },
    "contraindications": { "en": "Hypoglycemia", "cs": "Hypoglykémie" },
    "monitoring": { "en": "Glucose logs, hypoglycemia symptoms", "cs": "Glykemie, příznaky hypoglykémie" },
    "interactionsSummary": { "en": "Hypoglycemia risk with other antidiabetics", "cs": "Riziko hypoglykémie s jinými antidiabetiky" },
    "typicalDoseText": { "en": "Individualized units SC daily (educational)", "cs": "Individualizované jednotky s.c. denně (výukově)" },
    "tags": ["insulin", "diabetes"],
    "courseBlockId": "block-endo"
  },
  {
    "id": "drug-metformin",
    "name": { "en": "Metformin", "cs": "Metformin" },
    "class": { "en": "Biguanide", "cs": "Biguanid" },
    "indications": { "en": "Type 2 diabetes", "cs": "Diabetes 2. typu" },
    "mechanism": { "en": "Decreases hepatic gluconeogenesis, improves insulin sensitivity", "cs": "Snižuje jaterní glukoneogenezi, zlepšuje inzulinovou senzitivitu" },
    "adverseEffects": { "en": "GI upset, rare lactic acidosis", "cs": "GIT potíže, vzácně laktátová acidóza" },
    "contraindications": { "en": "Severe renal impairment", "cs": "Těžké renální selhání" },
    "monitoring": { "en": "eGFR annually", "cs": "eGFR ročně" },
    "interactionsSummary": { "en": "Caution with contrast dyes", "cs": "Opatrnost s kontrastními látkami" },
    "typicalDoseText": { "en": "500–1000 mg PO BID with meals (educational)", "cs": "500–1000 mg p.o. 2× denně s jídlem (výukově)" },
    "tags": ["biguanide", "diabetes"],
    "courseBlockId": "block-endo"
  },
  {
    "id": "drug-levothyroxine",
    "name": { "en": "Levothyroxine", "cs": "Levothyroxin" },
    "class": { "en": "T4 replacement", "cs": "Náhrada T4" },
    "indications": { "en": "Hypothyroidism", "cs": "Hypotyreóza" },
    "mechanism": { "en": "Replaces thyroid hormone, converted to T3", "cs": "Nahrazuje hormon štítné žlázy, konvertuje na T3" },
    "adverseEffects": { "en": "Hyperthyroid symptoms if over-replaced", "cs": "Příznaky hypertyreózy při nadbytku" },
    "contraindications": { "en": "Untreated adrenal insufficiency", "cs": "Neléčená adrenální insuficience" },
    "monitoring": { "en": "TSH every 6–8 weeks when adjusting", "cs": "TSH každých 6–8 týdnů při úpravách" },
    "interactionsSummary": { "en": "Absorption reduced by calcium/iron", "cs": "Absorpci snižuje vápník/železo" },
    "typicalDoseText": { "en": "~1.6 mcg/kg/day PO (educational)", "cs": "~1,6 mcg/kg/den p.o. (výukově)" },
    "tags": ["thyroid", "hormone"],
    "courseBlockId": "block-endo"
  },
  {
    "id": "drug-neostigmine",
    "name": { "en": "Neostigmine", "cs": "Neostigmin" },
    "class": { "en": "Acetylcholinesterase inhibitor", "cs": "Inhibitor acetylcholinesterázy" },
    "indications": { "en": "Myasthenia gravis, reversal of neuromuscular blockade", "cs": "Myasthenia gravis, reverze nervosvalové blokády" },
    "mechanism": { "en": "Inhibits AChE increasing acetylcholine", "cs": "Inhibuje AChE, zvyšuje acetylcholin" },
    "adverseEffects": { "en": "Bradycardia, bronchospasm, GI cramps", "cs": "Bradykardie, bronchospazmus, GIT křeče" },
    "contraindications": { "en": "Peritonitis, mechanical obstruction", "cs": "Peritonitida, mechanická obstrukce" },
    "monitoring": { "en": "Respiratory status, heart rate", "cs": "Respirační stav, srdeční frekvence" },
    "interactionsSummary": { "en": "Additive cholinergic effects", "cs": "Adice cholinergních účinků" },
    "typicalDoseText": { "en": "0.5–2.5 mg IV/IM (educational)", "cs": "0,5–2,5 mg i.v./i.m. (výukově)" },
    "tags": ["cholinergic", "ans"],
    "courseBlockId": "block-ans"
  },
  {
    "id": "drug-epinephrine",
    "name": { "en": "Epinephrine", "cs": "Adrenalin" },
    "class": { "en": "Non-selective adrenergic agonist", "cs": "Neselektivní adrenergní agonista" },
    "indications": { "en": "Anaphylaxis, cardiac arrest", "cs": "Anafylaxe, srdeční zástava" },
    "mechanism": { "en": "Stimulates alpha and beta receptors raising BP and CO", "cs": "Stimuluje alfa a beta receptory, zvyšuje TK a srdeční výdej" },
    "adverseEffects": { "en": "Tachycardia, tremor", "cs": "Tachykardie, třes" },
    "contraindications": { "en": "None in emergencies", "cs": "V urgentních stavech žádné" },
    "monitoring": { "en": "BP, HR, perfusion", "cs": "TK, TF, perfuze" },
    "interactionsSummary": { "en": "Arrhythmia risk with stimulants", "cs": "Riziko arytmie se stimulancii" },
    "typicalDoseText": { "en": "0.3–0.5 mg IM for anaphylaxis (educational)", "cs": "0,3–0,5 mg i.m. při anafylaxi (výukově)" },
    "tags": ["adrenergic", "ans", "emergency"],
    "courseBlockId": "block-ans"
  }
]
